• A review of the literature found two similar cases of delayed reactions to oxaliplatin occurring 20 and 10 hours after infusion respectively. The first case occurred after the initial dose and again with cycle 2. The second case happened following the sixth infusion.
The median cycles of oxaliplatin given before SAR developed was 10 (range, 2-29). Three fatalities (4.5%) were reported. We wish to report an unusual presentation of hypersensitivity to the initial dose of oxaliplatin, consisting of severe respiratory symptoms which occurred immediately after completion of the infusion and recurred again 19 hours later.
Case Report
A 69-year old Caucasian woman underwent a left hemicolectomy for a non-obstructing mass in the caecum. Histology showed a moderately differentiated adenocarcinoma extending through the bowel wall into the sub-serosa. Two of 9 sampled lymph nodes contained Because HSR reactions to platinum compounds are usually seen after multiple cycles, the mechanism is thought to be due to a Type I response, mediated by IgE. 3, 7 Immunemediated thrombocytopenia and haemolytic anemia have also been reported with oxaliplatin indicating a Type II hypersensitivity mediated by IgG and IgM. [7] [8] [9] [10] IgG mediated Type III reactions, resulting in symptoms such as chronic uricaria and fever, have been documented 7 .
Delayed reactions which can occur hours or even days after an oxaliplatin infusion have been reported. These are Type IV HSR mediated through T-cells and can present as contact dermatitis.
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The exact mechanism of our patient's reaction is unclear, but may involve immunemediated and non-immunologic mechanisms possibly including Type 1 and Type IV HSR. 7, 8 Prick and intradermal skin tests have been beneficial in detecting drug-specific IgE with platinum salts. 8 Skin testing was deemed unnecessary in our patient as we didn't intend to continue oxaliplatin therapy and the possible risk of anaphylaxis which has been reported following skin testing. 14 It has also been postulated that excess serotonin may play a role in inducing bronchospasm through serotonin receptors I and II.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Strategies such as premedication with corticosteroids and antihistamines and prolongation of the infusion rate have been used to prevent SAR after oxaliplatin use. 3, 16 Densensitization protocols have also been employed successfully. [16] [17] [18] However, despite these interventions, reactions have still occurred. Prior to making her decision to cease adjuvant chemotherapy, our patient was made fully aware of the options for continuing oxaliplatin-based chemotherapy and the potential risk of further serious and even fatal HSR even with preventative strategies. She was also given the option of continuing chemotherapy without oxaliplatin using single agent treatment with capecitabine or infusional fluorouracil and understood the potential survival benefits.
Conclusion
This is the first reported case of an immediate acute HSR with the initial dose of oxaliplatin followed by a similar delayed reaction 19 hours later. Due to the increasing clinical use of oxaliplatin in the adjuvant and metastatic settings, clinicians should be aware of this unusual, potentially life-threating HSR presentation.
M A N U S C R I P T A C C E P T E D

